A 120-kDa protein that blocks DNA termini has been purified from extracts of HeLa cells. This protein inhibits the action of a number of enzymes that catalyze reactions involving the 5' and 3' ends of DNA (DNA ligase, 3' and 5' exonucleases, and DNA polymerase a). The 120-kDa protein blocks the synthesis of long DNA chains that are normally formed during simian virus 40 DNA replication, causing the accumulation of small DNA fragments. The effects of this protein can be reversed by the addition of proliferating cell nuclear antigen and other protein fractions (activators).
The replication of simian virus 40 (SV40) DNA has been extensively reviewed (1, 2) , Since the establishment of an in vitro SV40 replication system (1) (2) (3) (4) (5) , a number of wellcharacterized proteins have been shown to play a direct role in SV40 DNA replication. In addition to the SV40-encoded large tumor antigen (SV40 T antigen) (3), proteins that have been purified from human cells include DNA polymerase a and DNA primase (6) , topoisomerases (topo) I and II (7), and a single-stranded (ss) DNA-binding protein (SSB) (8) (9) (10) . RNase H, a 5' to 3' exonuclease, and DNA ligase have been shown to be required for the formation of closed circular duplex DNA (11) .
Proliferating cell nuclear antigen (PCNA), a putative cellcycle-regulated protein, was shown to be essential in an SV40 in vitro replication system containing relatively crude fractions (12) . Furthermore, PCNA was required for leadingstrand DNA synthesis, since only small DNA fragments arising from the lagging strand accumulated in its absence (13) . In contrast, PCNA had no effect in a reconstituted system containing T antigen, HeLa SSB, topo I, and the DNA polymerase a-primase complex as purified components (14) . The different requirement for PCNA was traced to an elongation inhibitor protein, which was present in the crude fractions but not in the purified reconstituted system. The elongation inhibitor prevented the synthesis oflong DNA chains, which resulted in the accumulation of short DNA fragments [average length, 300 nucleotides (nt)]. Its effect could be reversed by PCNA and protein activators (14) .
In this report, we present the characterization of the elongation inhibitor protein. In addition, we have examined a number of enzymatic reactions that are affected by this inhibitor and have identified protein activator fractions that are essential for the reversal of the effects of this inhibitor.
MATERIALS AND METHODS
Preparations of Proteins and Nucleic Acids. Cytosolic extracts of HeLa cell, SV40 ori+ DNA (pSV01AEP), and SV40 T antigen were prepared as previously described (3 units/mg of protein). The above were prepared as described (11, 14) . Escherichia coli exonuclease III was purchased from Boehringer Mannheim Biochemicals.
Assays of Enzymatic Reactions and the Elongation Inhibitor.
The 5' to 3' exonuclease and DNA ligase were assayed as described (11 (14) , and the inhibitor fraction. After 60 min at 370C, aliquots were removed for gel electrophoresis of products and the determination of acid-insoluble material as described (14) . Cytoplasmic extracts of HeLa cells (100 ml, 30 mg of protein per ml) were adjusted to 0.2 M NaCl and loaded on a PC column (2.5 x 17 cm; 85 ml) equilibrated with buffer A (25 mM Tris-HCl, pH 7. mM NaCl (5 ml, 3.7 mg of protein, 1 x 104 units; specific activity, 2702 units/mg ofprotein) and then chromatographed on a double-stranded (ds) DNA-cellulose column (1.2 x 1.8 cm; 2 ml) equilibrated with buffer A containing 0.2 M NaCl. This column was eluted successively with 10 ml of buffer A containing 0.2, 0.4, 0.6, and 0.8 M NaCl. The inhibitor eluted with 0.4 M NaCl. This fraction was dialyzed against buffer A containing 0.025 M NaCl (3 ml, 1.77 mg of protein, 7.5 x 103 units; specific activity, 4237 units/mg of protein) and then centrifuged through a glycerol gradient. The dsDNAcellulose fraction (0.2 ml, 0.12 mg of protein) was layered onto a 5-ml 15-35% glycerol gradient containing buffer A plus 0.25 M NaCl and centrifuged at 45,000 x g for 24 hr at 4(C. Thirty fractions (0.17 ml each) were collected and assayed for the inhibitor. The inhibitor activity peaked in fractions 16-20, which were then pooled (0.85 ml, 40 Ag of protein, 283 units; specific activity, 7075 units/mg of protein). If the entire dsDNA-cellulose fraction had been carried through this step, a total of4.2 x 103 units would have been recovered. The final fraction of the elongation inhibitor was purified approximately 17-fold over the 0.7 M PC starting fraction with a yield of about 10%o.
Protein Assays. Protein concentrations were determined by using the Bio-Rad protein assay reagent. SDS/PAGE electrophoresis of protein fractions was carried out as described by Laemmli (16) , and protein bands were visualized using the ICN Rapid-Ag-Stain kit.
RESULTS
Properties of the Elongation Inhibitor. With increasing concentrations of the inhibitor, SV40 ori+ DNA synthesis decreased and shorter DNA chains accumulated (Fig. 1) . When PCNA was added, the size of the DNA products as well as the amount of DNA synthesis increased (Fig. 1) . Relatively low (nanogram) concentrations of PCNA could reverse the effects of large (microgram) amounts of the inhibitor, suggesting that PCNA may act catalytically. Increasing concentrations of the inhibitor appeared to decrease the length of DNA chains proportionally. In contrast, the synthesis of nearly full-length chains was stimulated by low (10 ng) concentrations of PCNA, which barely increased nucleotide incorporation. This marked increase in length is characteristic of a processive system. Assuming that each preparation was homogeneous and fully active, the PCNA activation was evident at molar concentrations that were 10-to 100-fold lower than the molar concentration of the inhibitor.
The Elongation Inhibitor Is a 120-kDa Protein. The dsDNAcellulose fraction was rechromatographed on a dsDNAcellulose column and eluted with a linear salt gradient (Fig.  2 ). Fractions were analyzed by SDS/PAGE ( Fig. 2A) and assayed for their ability to block SV40 replication (Fig. 2B) and inhibit the action of exonuclease III (Fig. 2C) . The peak of inhibitory activity for the two activities coincided with the presence of a 120-kDa protein band. No other protein coincided with the inhibitory activity across the gradient.
Gel-filtration chromatography was performed to define the native size and structure of the elongation inhibitor. The 120-kDa elongation inhibitor was eluted from a dsDNAcellulose column with a NaCl linear gradient and concentrated by ammonium sulfate precipitation (60%). The sample (0.22 mg) was chromatographed on Sephacryl S200-SF (0.7 x 50 cm; Pharmacia) at 40C in buffer containing 25 Tris HCl (pH 7.5), 0.25 M NaCl, 1 mM dithiothreitol, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 0.2 ,ug of antipain per ml, 0.1 gg of leupeptin per ml, and 0.02% sodium azide. Active fractions containing the 120-kDa elongation inhibitor eluted in a fraction corresponding to a Stokes radius of 59.5 A. Based on a sedimentation coefficient of 4.2S (14) , the native molecular mass of the elongation inhibitor is 138 kDa as determined by the Siegel and Monty equation (17) . The 138-kDa fraction was active both as an elongation inhibitor in the SV40 DNA replication assay in vitro and in blocking the action of exonuclease III. On SDS/PAGE analysis, the 138-kDa fraction migrated as a 120-kDa protein (data not shown).
Replication Elongation Inhibitor Blocks Enzymatic Reactions That Act at the Ends of DNA. The dsDNA-cellulose fraction was separated by glycerol gradient centrifugation, and the fractions were assayed for their ability to inhibit the replication of SV40 ori+ DNA in the presence and absence of PCNA. The inhibitor activity peaked in fraction 18 of the glycerol gradient (Fig. 3) . The dsDNA-cellulose inhibitor activity, which was loaded on to the gradient, was reversed by PCNA (Fig. 3, lanes B and C) . In contrast, the inhibitory activity offraction 18 was only marginally reversed by PCNA (Fig. 3, lanes 16-20) . Glycerol stimulated DNA synthesis in the presence of PCNA, and this observation is discussed in more detail below.
We examined the effect of the inhibitor on a number of enzymatic activities that occur at the ends of DNA. The inhibitor blocked the action of exonuclease III (Fig. 4A) , the elongation of a primed DNA template by DNA polymerase a, the action of DNA ligase (using dA4000-[5'-32P]dT50 as substrate), and the HeLa 5' to 3' exonuclease [the enzyme that removes RNA primers in the SV40 replication reaction (11)] (Fig. 4B) . When these enzyme activities were used to monitor the sedimentation of the elongation inhibitor in the glycerol gradient, the profile of inhibitory activity was the same as that observed with the SV40 replication system (Fig. 3) .
Other Properties of the Elongation Inhibitor. The elongation inhibitor (glycerol gradient fractions [16] [17] [18] [19] [20] as previously described (11) . Reactions with 2 Al of the gradient fractions were preincubated for 5 min at 25°C, and then 2 units of the 5' to 3' exonuclease was added. Incubations were for 15 min at 37°C followed by the addition of 20 ,ul of bovine serum albumin (5 mg/ml) and 160 ,ul of ethanol. The mixtures were stored at -80°C for 30 min and then centrifuged, and the supernatant was measured for the ethanol-soluble 32p. The 100o value was equivalent to the release of 50 fmol of 32p. The assay for DNA ligase activity was carried out in reaction mixtures (50 ,ul) as previously described (11) . After 5 min of preincubation with 2 p.1 of gradient fraction at 25°C, DNA ligase (0.04 unit) was added, and the reaction mixtures were incubated at 37°C for 30 min. The DNA ligase activity was determined as previously described (11) . The 100%o value in this assay was equal to 15 fmol of 32p rendered resistant to alkaline phosphatase. Each glycerol gradient fraction (3 ,ul) was used for the DNA polymerase a (Pol a) elongation assay; the incorporation of 12 pmol of dTMP was equivalent to 100%. activity was shown to be a property of the 120-kDa protein.
The glycerol gradient fraction of the inhibitor was subjected to SDS/PAGE, transferred to nitrocellulose, and probed with dA4wo0[5'-32P]dT5o. The only labeled band detected corresponded to a protein of 120 kDa (data not shown).
The elongation inhibitor is a basic protein with an isoelectric point estimated to be pH 9.0 or greater using the PhastGel isoelectric focusing 3-9 system (Pharmacia).
The inhibitor was resistant to N-ethylmaleimide and sensitive to heat (50o inactivated after 55 sec at 500C). Both the binding of dA400-[5_-32P]dT50 and the inhibition of replication were heat inactivated at the same rate. The complex formed with the inhibitor and the singly primed 4X174 DNA was stable to gel filtration and retained its ability to block both exonuclease III and DNA polymerase a-catalyzed reactions. The addition of HeLa SSB or ATP did not affect the binding of the inhibitor to primed DNA (data not shown).
Resolution of the Elongation Inhibitor from a PCNAMediated Activator. The inhibitor activity in fractions [16] [17] [18] [19] [20] from the glycerol gradient was only marginally reversed by PCNA in replication reactions containing T antigen, the 0.3 M NaCl PC fraction, topo I, and the HeLa SSB (Fig. 3) . In contrast, fractions [10] [11] [12] from the gradient stimulated the formation of longer DNA products in the presence of PCNA. Therefore the influence of fractions 10-12 in overcoming the effect of the fraction [16] [17] [18] [19] [20] inhibitor was examined ( centrifugation. This activator fraction has been named activator fraction I. As previously shown (14) , the dsDNA-cellulose fraction of the inhibitor (prior to the glycerol gradient step) blocked replication reactions in which immunopurified DNA polymerase a-primase complex was used instead of the 0.3 M NaCl PC fraction. When the immunopurified polymerase aprimase complex was used, the inhibitor activity could not be reversed by the addition of PCNA and the glycerol gradient activator fraction (data not shown). This suggests that another activator, which we have called activator fraction II, is present in the 0.3 M NaCl PC fraction.
DISCUSSION
In this report, we have further characterized an elongation inhibitor that acts at the end of DNA chains. This protein interferes with enzymatic reactions that occur at 3' or 5' ends ofDNA, such as the elongation of a primed template by DNA polymerase a, the joining reaction catalyzed by DNA ligase, and both 5' to 3' and 3' to 5' exonuclease reactions. The unusual property of the elongation inhibitor is that its action in the SV40 system is reversed by a combination of PCNA and other protein activators. The PCNA-dependent reversal can also be demonstrated directly either in reactions catalyzed by DNA polymerase a or exonuclease III by using primed 4X174 DNA as a substrate for both systems (data not shown).
SV40 DNA replication by relatively crude fractions in the absence of PCNA is primarily restricted to the formation of small DNA fragments from lagging-strand DNA synthesis (13) . We have made similar observations with reaction mixtures lacking PCNA but containing the 0.3 M NaCl PC fraction, purified HeLa SSB, topo I (or topo II), T antigen, and the inhibitor (data not presented). At present, it is not clear why only lagging-strand synthesis is observed in the absence of PCNA, since the elongation inhibitor does not appear to discriminate between leading-and lagging-strand DNA synthesis. In the SV40 DNA replication system, we have shown that small DNA fragments synthesized during a pulse period (in reactions containing 0.3 M NaCl PC fraction, HeLa SSB, topo I, T antigen, and the inhibitor but no PCNA) can be chased into long DNA products by the addition of PCNA and the activator fraction I (data not shown). This suggests that the reversal of the action of the inhibitor allows DNA ligase and the 5' to 3' exonuclease to synthesize longer DNA products from the short lagging-strand products. In the SV40 replication system reconstituted with purified components, the 5' to 3' exonuclease and DNA ligase are essential for the synthesis of full-length and circular DNA products. In their absence both small Okazaki size (200 nt) and half-length (1700 nt) products were formed using pSV01A&EP DNA as the template (11) .
Low concentrations of PCNA in the presence of the activator fractions reversed the effects of relatively large amounts of the inhibitor. The amount of elongation activator protein I isolated by glycerol gradient centrifugation was at least 40-fold lower than the amount of elongation inhibitor isolated (Fig. 3) . These observations suggest that the activator may act catalytically in reversing the effect of the inhibitor.
Recently, Tsurimoto and Stillman (18) reported the isolation of a complex (containing four polypeptides of 37, 41, 100, and 140 kDa) required for the synthesis of long DNA products. In its absence, short, lagging-strand DNA fragments were formed by a crude receptor fraction, which contained PCNA as well as polymerase-primase, HeLa SSB, and other factors. These observations are analogous to our findings with reactions containing inhibitor but lacking activators.
The activation of primer ends described here has some similarities to DNA synthesis catalyzed by the DNA polymerase III system of E. coli. In this system, the y-8 complex catalytically transfers the dnaN gene product (,B subunit or factor I) to the 3'-OH end ofa primed template in the presence of ATP. A complex that includes at least the primed template and the dnaN gene product is then utilized by DNA polymerase III in the elongation reaction, which results in the processive growth of chains at high rates (19) (20) (21) . In the absence of the dnaN gene product, DNA polymerase III acts distributively. It is possible that PCNA, the inhibitor, and the elongation activators act in a manner analogous to the y-8 complex and the dnaN protein.
Further investigation of the mechanism by which the activators and PCNA interact with the elongation inhibitor will be required to understand the control of DNA elongation in the SV40 replication system. Note Added in Proof. We have identified the elongation inhibitor as poly(ADP-ribose) polymerase and activator II as PCNA-dependent DNA polymerase 8.
